bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary information from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Authors: Shibata Tomohiro , Watari Kosuke , Kawahara Akihiko , Sudo Tomoya , Hattori Satoshi , Murakami Yuichi , Izumi Hiroto , Itou Junji , Toi Masakazu , Akiba Jun , Akagi Yoshito , Tanaka Maki , Kuwano Michihiko , Ono Mayumi
Published: April 2023

Supplementary Materials and Methods
Supplementary Table S3 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Authors: Shibata Tomohiro , Watari Kosuke , Kawahara Akihiko , Sudo Tomoya , Hattori Satoshi , Murakami Yuichi , Izumi Hiroto , Itou Junji , Toi Masakazu , Akiba Jun , Akagi Yoshito , Tanaka Maki , Kuwano Michihiko , Ono Mayumi
Published: April 2023

IC50 values of fulvestrant, everolimus, AZD8055 and U0126 in ER(+)/HER2(-) and ER(-)/HER2(+) human breast cancer cell lines.
Supplementary Figure S3 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Authors: Shibata Tomohiro , Watari Kosuke , Kawahara Akihiko , Sudo Tomoya , Hattori Satoshi , Murakami Yuichi , Izumi Hiroto , Itou Junji , Toi Masakazu , Akiba Jun , Akagi Yoshito , Tanaka Maki , Kuwano Michihiko , Ono Mayumi
Published: April 2023

Comparison of body weights of 4 experimental groups on day 20 after inoculation. Body weights graph corresponds to Fig. 5A-D.
Supplementary Figure S2 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Authors: Shibata Tomohiro , Watari Kosuke , Kawahara Akihiko , Sudo Tomoya , Hattori Satoshi , Murakami Yuichi , Izumi Hiroto , Itou Junji , Toi Masakazu , Akiba Jun , Akagi Yoshito , Tanaka Maki , Kuwano Michihiko , Ono Mayumi
Published: April 2023

The effect of everolimus on expression and phosphorylation of YBX1, ERK/p90RSK and AKT/mTOR signaling molecules in six TNBC cell lines.
Supplementary Figure S1 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Authors: Shibata Tomohiro , Watari Kosuke , Kawahara Akihiko , Sudo Tomoya , Hattori Satoshi , Murakami Yuichi , Izumi Hiroto , Itou Junji , Toi Masakazu , Akiba Jun , Akagi Yoshito , Tanaka Maki , Kuwano Michihiko , Ono Mayumi
Published: April 2023

Expression of YBX1, pYBX1 and downstream molecules in 6 human breast cancer cell lines.
SupplementaryTable S2 from Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer
Authors: Kawai Yoshihisa , Imada Kenjiro , Akamatsu Shusuke , Zhang Fan , Seiler Roland , Hayashi Tetsutaro , Leong Jeffrey , Beraldi Eliana , Saxena Neetu , Kretschmer Alexander , Oo Htoo Zarni , Contreras-Sanz Alberto , Matsuyama Hideyasu , Lin Dong , Fazli Ladan , Collins Colin C. , Wyatt Alexander W. , Black Peter C. , Gleave Martin E.
Published: April 2023

Probes used in the PCR assays
Supplementary Table S1 from Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer
Authors: Kawai Yoshihisa , Imada Kenjiro , Akamatsu Shusuke , Zhang Fan , Seiler Roland , Hayashi Tetsutaro , Leong Jeffrey , Beraldi Eliana , Saxena Neetu , Kretschmer Alexander , Oo Htoo Zarni , Contreras-Sanz Alberto , Matsuyama Hideyasu , Lin Dong , Fazli Ladan , Collins Colin C. , Wyatt Alexander W. , Black Peter C. , Gleave Martin E.
Published: April 2023

Primary antibodies used in this study
Supplementary Information from Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer
Authors: Kawai Yoshihisa , Imada Kenjiro , Akamatsu Shusuke , Zhang Fan , Seiler Roland , Hayashi Tetsutaro , Leong Jeffrey , Beraldi Eliana , Saxena Neetu , Kretschmer Alexander , Oo Htoo Zarni , Contreras-Sanz Alberto , Matsuyama Hideyasu , Lin Dong , Fazli Ladan , Collins Colin C. , Wyatt Alexander W. , Black Peter C. , Gleave Martin E.
Published: April 2023

Supplementary Methods
Figure S5 from Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer
Authors: Kawai Yoshihisa , Imada Kenjiro , Akamatsu Shusuke , Zhang Fan , Seiler Roland , Hayashi Tetsutaro , Leong Jeffrey , Beraldi Eliana , Saxena Neetu , Kretschmer Alexander , Oo Htoo Zarni , Contreras-Sanz Alberto , Matsuyama Hideyasu , Lin Dong , Fazli Ladan , Collins Colin C. , Wyatt Alexander W. , Black Peter C. , Gleave Martin E.
Published: April 2023

PEG10 promotes migration and invasion of bladder cancer cells.
Figure S4 from Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer
Authors: Kawai Yoshihisa , Imada Kenjiro , Akamatsu Shusuke , Zhang Fan , Seiler Roland , Hayashi Tetsutaro , Leong Jeffrey , Beraldi Eliana , Saxena Neetu , Kretschmer Alexander , Oo Htoo Zarni , Contreras-Sanz Alberto , Matsuyama Hideyasu , Lin Dong , Fazli Ladan , Collins Colin C. , Wyatt Alexander W. , Black Peter C. , Gleave Martin E.
Published: April 2023

PEG10 promotes proliferation of bladder cancer cells when tRb protein is absent.
Supplementary Table 1 from An Antibody-Tumor Necrosis Factor Fusion Protein that Synergizes with Oxaliplatin for Treatment of Colorectal Cancer
Authors: Bajic Davor , Chester Kerry , Neri Dario
Published: April 2023

Supplementary Table 1 in PDF
Supplementary Data from An Antibody-Tumor Necrosis Factor Fusion Protein that Synergizes with Oxaliplatin for Treatment of Colorectal Cancer
Authors: Bajic Davor , Chester Kerry , Neri Dario
Published: April 2023

sequences and figures
Table S1 from Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
Authors: Kotanides Helen , Sattler Rose Marie , Lebron Maria B. , Carpenito Carmine , Shen Juqun , Li Jingxing , Surguladze David , Haidar Jaafar N. , Burns Colleen , Shen Leyi , Inigo Ivan , Pennello Anthony L. , Forest Amelie , Chen Xinlei , Chin Darin , Sonyi Andreas , Topper Michael , Boucher Lauren , Sharma Prachi , Zhang Yiwei , Burtrum Douglas , Novosiadly Ruslan D. , Ludwig Dale L. , Plowman Gregory D. , Kalos Michael
Published: April 2023

Table S1 shows human immune effector Fcg and C1Q binding EC50 (nM)
Supplementary Tables from High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers
Authors: Riviere Paul , Goodman Aaron M. , Okamura Ryosuke , Barkauskas Donald A. , Whitchurch Theresa J. , Lee Suzanna , Khalid Noor , Collier Rachel , Mareboina Manvita , Frampton Garrett M. , Fabrizio David , Sharabi Andrew B. , Kato Shumei , Kurzrock Razelle
Published: April 2023

Supplementary Tables
Supplementary Script 1 from High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers
Authors: Riviere Paul , Goodman Aaron M. , Okamura Ryosuke , Barkauskas Donald A. , Whitchurch Theresa J. , Lee Suzanna , Khalid Noor , Collier Rachel , Mareboina Manvita , Frampton Garrett M. , Fabrizio David , Sharabi Andrew B. , Kato Shumei , Kurzrock Razelle
Published: April 2023

Supplementary Script 1
Figure S7 from Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
Authors: Kotanides Helen , Sattler Rose Marie , Lebron Maria B. , Carpenito Carmine , Shen Juqun , Li Jingxing , Surguladze David , Haidar Jaafar N. , Burns Colleen , Shen Leyi , Inigo Ivan , Pennello Anthony L. , Forest Amelie , Chen Xinlei , Chin Darin , Sonyi Andreas , Topper Michael , Boucher Lauren , Sharma Prachi , Zhang Yiwei , Burtrum Douglas , Novosiadly Ruslan D. , Ludwig Dale L. , Plowman Gregory D. , Kalos Michael
Published: April 2023

Figure S7 shows enhanced T cells in 7A5 treated L55 established tumor xenografts
Figure S4 from Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
Authors: Kotanides Helen , Sattler Rose Marie , Lebron Maria B. , Carpenito Carmine , Shen Juqun , Li Jingxing , Surguladze David , Haidar Jaafar N. , Burns Colleen , Shen Leyi , Inigo Ivan , Pennello Anthony L. , Forest Amelie , Chen Xinlei , Chin Darin , Sonyi Andreas , Topper Michael , Boucher Lauren , Sharma Prachi , Zhang Yiwei , Burtrum Douglas , Novosiadly Ruslan D. , Ludwig Dale L. , Plowman Gregory D. , Kalos Michael
Published: April 2023

Figure S4 shows 7A5 enhances the memory T cell population
Figure S1 from Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
Authors: Kotanides Helen , Sattler Rose Marie , Lebron Maria B. , Carpenito Carmine , Shen Juqun , Li Jingxing , Surguladze David , Haidar Jaafar N. , Burns Colleen , Shen Leyi , Inigo Ivan , Pennello Anthony L. , Forest Amelie , Chen Xinlei , Chin Darin , Sonyi Andreas , Topper Michael , Boucher Lauren , Sharma Prachi , Zhang Yiwei , Burtrum Douglas , Novosiadly Ruslan D. , Ludwig Dale L. , Plowman Gregory D. , Kalos Michael
Published: April 2023

Figure S1 shows the 7A5 antibody amino acid sequence
Supplementary Figure 1 from High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers
Authors: Riviere Paul , Goodman Aaron M. , Okamura Ryosuke , Barkauskas Donald A. , Whitchurch Theresa J. , Lee Suzanna , Khalid Noor , Collier Rachel , Mareboina Manvita , Frampton Garrett M. , Fabrizio David , Sharabi Andrew B. , Kato Shumei , Kurzrock Razelle
Published: April 2023

Supplementary Figure 1
Supplementary Methods from The Discovery of SWI/SNF Chromatin Remodeling Activity as a Novel and Targetable Dependency in Uveal Melanoma
Authors: Rago Florencia , Elliott GiNell , Li Ailing , Sprouffske Kathleen , Kerr Grainne , Desplat Aurore , Abramowski Dorothee , Chen Julie T. , Farsidjani Ali , Xiang Kay X. , Bushold Geoffrey , Feng Yun , Shirley Matthew D. , Bric Anka , Vattay Anthony , Möbitz Henrik , Nakajima Katsumasa , Adair Christopher D. , Mathieu Simon , Ntaganda Rukundo , Smith Troy , Papillon Julien P.N. , Kauffmann Audrey , Ruddy David A. , Bhang Hyo-eun C. , Castelletti Deborah , Jagani Zainab
Published: April 2023

Additional method details for ATAC-Seq Data Analysis and ChIP-qPCR
Figure S3 from Inhibition of EZH2 Enhances the Antitumor Efficacy of Metformin in Prostate Cancer
Authors: Kong Yifan , Zhang Yanquan , Mao Fengyi , Zhang Zhuangzhuang , Li Zhiguo , Wang Ruixin , Liu Jinghui , Liu Xiaoqi
Published: April 2023

Combination of GSK126 and low-concentration metformin
Table S1 from Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding
Authors: Puro Robyn J. , Bouchlaka Myriam N. , Hiebsch Ronald R. , Capoccia Benjamin J. , Donio Michael J. , Manning Pamela T. , Frazier William A. , Karr Robert W. , Pereira Daniel S.
Published: April 2023

Table S1 shows the affinity and kinetics of AO-176 and AO-104 to human and cynomolgus monkey CD47 determined by surface plasmon resonance
Figure S5 from Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding
Authors: Puro Robyn J. , Bouchlaka Myriam N. , Hiebsch Ronald R. , Capoccia Benjamin J. , Donio Michael J. , Manning Pamela T. , Frazier William A. , Karr Robert W. , Pereira Daniel S.
Published: April 2023

Figure S5 demonstrates that AO-176 does not mediate antibody dependent cell cytotoxicity of tumor cells
Figure S3 from Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding
Authors: Puro Robyn J. , Bouchlaka Myriam N. , Hiebsch Ronald R. , Capoccia Benjamin J. , Donio Michael J. , Manning Pamela T. , Frazier William A. , Karr Robert W. , Pereira Daniel S.
Published: April 2023

Figure S3 shows the specificity of AO-176 for human CD47
Figure S2 from Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding
Authors: Puro Robyn J. , Bouchlaka Myriam N. , Hiebsch Ronald R. , Capoccia Benjamin J. , Donio Michael J. , Manning Pamela T. , Frazier William A. , Karr Robert W. , Pereira Daniel S.
Published: April 2023

Figure S2 shows that AO-176 does not bind to mouse CD47
Figure S4 from Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity
Authors: Zheng Zeliang , Okada Ryuhei , Kobayashi Hisataka , Nagaya Tadanobu , Wei Junxia , Zhou Qi , Lee Fred , Bera Tapan K. , Gao Yun , Kuhlman William , Tai Chin-Hsien , Pastan Ira
Published: April 2023

Rh measurements
Figure S4 from An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance
Authors: Deng Shanshan , Krutilina Raisa I. , Wang Qinghui , Lin Zongtao , Parke Deanna N. , Playa Hilaire C. , Chen Hao , Miller Duane D. , Seagroves Tiffany N. , Li Wei
Published: April 2023

Figure S4 shows that FACS analysis profiles of MDA-MB-231 and MDA-MB-468 TNBC cells following treatment with vehicle (Control), colchicine or paclitaxel, showing VERU-111 induces G2/M checkpoint arrest and apoptosis in TNBC cells. (A) Representative cell cycle distribution images after VERU-111 (10, 20, 50 and 100 nM), colchicine (100 nM) and paclitaxel (100 nM) treatment. Cells were treated for 24 h and stained with anti-phospho-histone H3 (Ser10) and propidium iodide (PI). (B) Representative FACS analysis profiles of apoptotic TNBC cells after 24 h treatment with VERU-111, colchicine or paclitaxel as detected by Annexin-V-FITC/PI staining. (C) Representative FACS analysis profiles of apoptotic TNBC cells after treating with 100 nM VERU-111 for 24, 48 or 72 h, cells were stained with Annexin-V-FITC and PI.
Figure S1 from An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance
Authors: Deng Shanshan , Krutilina Raisa I. , Wang Qinghui , Lin Zongtao , Parke Deanna N. , Playa Hilaire C. , Chen Hao , Miller Duane D. , Seagroves Tiffany N. , Li Wei
Published: April 2023

Figure S1 shows that VERU-111 inhibits TNBC cell migration and invasion at 16 nM. (A) Representative images of migration assays showing MDA-MB-231 (upper panel) and MDA-MB-468 (lower panel) cells treated with VERU-111 (16 nM) for 24 h and 48 h, respectively, that have migrated through transwell membrane inserts. (B) Representative images of invasion assays showing MDA-MB-231 (upper panel) and MDA-MB-468 (lower panel) cells treated with VERU-111 (16 nM) for 24 h and 48 h, respectively, using Matrigel-coated transwell membrane inserts. All data are presented as the grand mean {plus minus} SEM of three independent experiments, with p-values determined relative to the Control group (normalized to 100%), scale bar = 100 µm.
Table S4 from Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases
Authors: Koivu Marika K.A. , Chakroborty Deepankar , Tamirat Mahlet Z. , Johnson Mark S. , Kurppa Kari J. , Elenius Klaus
Published: April 2023

Table S4 shows drug sensitivity data for ERBB mutant and wild-type cell lines.
Table S3 from Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases
Authors: Koivu Marika K.A. , Chakroborty Deepankar , Tamirat Mahlet Z. , Johnson Mark S. , Kurppa Kari J. , Elenius Klaus
Published: April 2023

Table S3 shows primers used for site-directed mutagenesis.
Supplementary Data from HDP-101, an Anti-BCMA Antibody–Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells
Authors: Figueroa-Vazquez Vianihuini , Ko Jonathan , Breunig Christian , Baumann Anja , Giesen Nicola , Pálfi Anikó , Müller Christoph , Lutz Christian , Hechler Torsten , Kulke Michael , Müller-Tidow Carsten , Krämer Alwin , Goldschmidt Hartmut , Pahl Andreas , Raab Marc S.
Published: April 2023

Supplementary Table and Figures
Table S1 from Design of a Cytotoxic Neuroblastoma-Targeting Agent Using an Enzyme Acting on Polysialic Acid Fused to a Toxin
Authors: Lehti Timo A. , Pajunen Maria I. , Jokilammi Anne , Korja Miikka , Lilie Hauke , Vettenranta Kim , Finne Jukka
Published: April 2023

Table S1 shows the primer sequences used for cloning and sequencing.
Figure S4 from Design of a Cytotoxic Neuroblastoma-Targeting Agent Using an Enzyme Acting on Polysialic Acid Fused to a Toxin
Authors: Lehti Timo A. , Pajunen Maria I. , Jokilammi Anne , Korja Miikka , Lilie Hauke , Vettenranta Kim , Finne Jukka
Published: April 2023

Figure S4 shows the stability of DT386F-endoNA2 in human serum.
Table S2 from Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma
Authors: Martín-Broto Javier , Pousa Antonio López , Brohl Andrew S. , Van Tine Brian A. , Powers Benjamin , Stacchiotti Silvia , Blay Jean-Yves , Hu James S. , Oakley Gerard J. , Wang Hong , Szpurka Anna M. , Levy Donna E. , Mo Gary , Ceccarelli Matteo , Jones Robin L.
Published: April 2023

Treatment-emergent adverse events reported in {greater than or equal to}10% patients.
Table S1 from Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma
Authors: Martín-Broto Javier , Pousa Antonio López , Brohl Andrew S. , Van Tine Brian A. , Powers Benjamin , Stacchiotti Silvia , Blay Jean-Yves , Hu James S. , Oakley Gerard J. , Wang Hong , Szpurka Anna M. , Levy Donna E. , Mo Gary , Ceccarelli Matteo , Jones Robin L.
Published: April 2023

Immunohistochemistry H-score changes for PDGFRα and PDGFRβ.
Supplementary figures from A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers
Authors: Kawakami Masanori , Mustachio Lisa Maria , Chen Yulong , Chen Zibo , Liu Xiuxia , Wei Cheng-Hsin , Roszik Jason , Kittai Adam S. , Danilov Alexey V. , Zhang Xiaoshan , Fang Bingliang , Wang Jing , Heymach John V. , Tyutyunyk-Massey Liliya , Freemantle Sarah J. , Kurie Jonathan M. , Liu Xi , Dmitrovsky Ethan
Published: April 2023

Supplementary figures
Supplementary Data and Methods from Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy
Authors: Werner Christian K. , Nna Uchechi J. , Sun Hanshi , Wilder-Romans Kari , Dresser Joseph , Kothari Ayesha U. , Zhou Weihua , Yao Yangyang , Rao Arvind , Stallard Stefanie , Koschmann Carl , Bor Tarik , Debinski Waldemar , Hegedus Alexander M. , Morgan Meredith A. , Venneti Sriram , Baskin-Bey Edwina , Spratt Daniel E. , Colman Howard , Sarkaria Jann N. , Chinnaiyan Arul M. , Eisner Joel R. , Speers Corey , Lawrence Theodore S. , Strowd Roy E. , Wahl Daniel R.
Published: April 2023

Supplementary Figure S1: Additional expression data and comparisons of AR expression by subtype, age, sex, and common molecular alterations. Supplementary Figure S2. Tumor growth plots and mice weights for in vivo studies. Supplementary Figure S3: Heat map of down-regulated genes from the GBM 26 RNA-seq experiment. Supplementary Figure S4: Effects of seviteronel on dsDNA break repair in AR-positive and negative models post-radiation. Supplementary Figure S5: Effects of enzalutamide on dsDNA break repair in AR-positive and negative models post-radiation. Supplementary Figure S6. Effects of enzalutamide and seviteronel on alkaline tail moment in AR-positive models post-radiation. Method: alkaline comet assay.
Table S3 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Authors: Busacca Sara , O'Regan Laura , Singh Anita , Sharkey Annabel J. , Dawson Alan G. , Dzialo Joanna , Parsons Aimee , Kumar Neelam , Schunselaar Laurel M. , Guppy Naomi , Nakas Apostolos , Sheaff Michael , Mansfield Aaron S. , Janes Sam M. , Baas Paul , Fry Andrew M. , Fennell Dean A.
Published: April 2023

Patient characteristics
Figure S7 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Authors: Busacca Sara , O'Regan Laura , Singh Anita , Sharkey Annabel J. , Dawson Alan G. , Dzialo Joanna , Parsons Aimee , Kumar Neelam , Schunselaar Laurel M. , Guppy Naomi , Nakas Apostolos , Sheaff Michael , Mansfield Aaron S. , Janes Sam M. , Baas Paul , Fry Andrew M. , Fennell Dean A.
Published: April 2023

Western blot images for replicates. Replicate images for figure 1, figure 2 and figure 3.
Figure S6 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Authors: Busacca Sara , O'Regan Laura , Singh Anita , Sharkey Annabel J. , Dawson Alan G. , Dzialo Joanna , Parsons Aimee , Kumar Neelam , Schunselaar Laurel M. , Guppy Naomi , Nakas Apostolos , Sheaff Michael , Mansfield Aaron S. , Janes Sam M. , Baas Paul , Fry Andrew M. , Fennell Dean A.
Published: April 2023

Cyclin B expression is not altered after silencing of BRCA1 or treatment with vinorelbine. Western blots showing expression of cyclin B in MSTO-211H and REN cells 24 hours after silencing, and treatment of parental and resistant cells with vinorelbine 50nM (REN/RVR) or 100 nM (MSTO-211H/MVR) for 48 hours.
Figure S4 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Authors: Busacca Sara , O'Regan Laura , Singh Anita , Sharkey Annabel J. , Dawson Alan G. , Dzialo Joanna , Parsons Aimee , Kumar Neelam , Schunselaar Laurel M. , Guppy Naomi , Nakas Apostolos , Sheaff Michael , Mansfield Aaron S. , Janes Sam M. , Baas Paul , Fry Andrew M. , Fennell Dean A.
Published: April 2023

Prognostic effect of BRCA1 and MAD2L1. Kaplan Meier curve for overall survival (OS) in patients (n=48) showing survival in patients who were negative for both BRCA1 and MAD2L1 compared to patients positive for either BRCA1 or MAD2L1 and in patients negative for both BRCA1 and MAD2L1 vs patients positive for both BRCA1 and MAD2L1 vs patients negative for either BRCA1 or MAD2L1
Supplementary Chemical Structures from MMAE Delivery Using the Bicycle Toxin Conjugate BT5528
Authors: Bennett Gavin , Brown Amy , Mudd Gemma , Huxley Philip , Van Rietschoten Katerine , Pavan Silvia , Chen Liuhong , Watcham Sophie , Lahdenranta Johanna , Keen Nicholas
Published: April 2023

Supplementary Chemical Structures provides an inventory and structural diagrams of all Bicycle conjugates used in paper
Figure S2 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Authors: Busacca Sara , O'Regan Laura , Singh Anita , Sharkey Annabel J. , Dawson Alan G. , Dzialo Joanna , Parsons Aimee , Kumar Neelam , Schunselaar Laurel M. , Guppy Naomi , Nakas Apostolos , Sheaff Michael , Mansfield Aaron S. , Janes Sam M. , Baas Paul , Fry Andrew M. , Fennell Dean A.
Published: April 2023

Silencing of BRCA1 and MAD2L1 leads to resistance to docetaxel. A) 24 hours following transfection, cells were treated with docetaxel 20 nM for a further 24 hours and caspase 3 activity measured. Data were normalised to untreated siNT control. MSTO-211H: siNT NT vs siNT DOCE p=0.0003; siBRCA1 NT vs siBRCA1 DOCE p=0.0206; siNT DOCE vs siBRCA1 DOCE p=0.0013. REN: siNT NT vs siNT DOCE p<0.0001; siBRCA1 NT vs siBRCA1 DOCE p=0.0069; siNT DOCE vs siBRCA1 DOCE p<0.0001. B) Cells were treated with docetaxel 20 nM for 24 hours and caspase 3 activity measured. Data were normalised to parental cells. MSTO-211H NT vs MSTO-211H DOCE p<0.0001; MSTO211H DOCE vs MVR DOCE p<0.0001. REN NT vs REN DOCE p<0.0001; REN VNB vs RVR VNB p<0.0001; RVR NT vs RVR DOCE p=0.0069. C) The cells indicated were treated with 20 nM docetaxel before time-lapse imaging using phase contrast microscopy. Cells were imaged every 15 mins for 25 h following addition of drug. Control cells were treated with DMSO. Stills from representative movies are shown. Scale bar 200μm.
Figure S3 from Hormone-Dependent Prostate Cancers are Dependent on Rac Signaling for Growth and Survival
Authors: Goka Erik T. , Mesa Lopez Dayrelis T. , Lippman Marc E.
Published: April 2023

Supplemental Figure 3. Cellular proliferation assays of (A) LnCap and (B) VCaP cells transfected with control siRNA (siNSC) or Rac1 targeted siRNA (siRac1).
Supplementary Data from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
Authors: Perera Samanthi A. , Kopinja Johnny E. , Ma Yanhong , Muise Eric S. , Laskey Jason , Chakravarthy Kalyan , Chen Yiping , Cui Long , Presland Jeremy , Sathe Manjiri , Javaid Sarah , Minnihan Ellen C. , Ferguson Heidi M. , Piesvaux Jennifer , Pan Bo-Sheng , Zhao Shuxia , Sharma Sharad K. , Woo Hyun Chong , Pucci Vincenzo , Knemeyer Ian , Cemerski Saso , Cumming Jared , Trotter B. Wesley , Tse Archie , Khilnani Anuradha , Ranganath Sheila , Long Brian J. , Bennett David Jonathan , Addona George H.
Published: April 2023

Supplementary Methods and Figures
Supplementary Table 1 from Phosphoproteomics Identifies PI3K Inhibitor–selective Adaptive Responses in Pancreatic Cancer Cell Therapy and Resistance
Authors: Cintas Célia , Douche Thibault , Dantes Zahra , Mouton-Barbosa Emmanuelle , Bousquet Marie-Pierre , Cayron Coralie , Therville Nicole , Pont Frédéric , Ramos-Delgado Fernanda , Guyon Camille , Garmy-Susini Barbara , Cappello Paola , Burlet-Schiltz Odile , Hirsch Emilio , Gomez-Brouchet Anne , Thibault Benoît , Reichert Maximilian , Guillermet-Guibert Julie
Published: April 2023

Supplementary Table 1 contains the list of files deposited on PRIDE Proteome X Change under the number PXD008410.
Table S2 from Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK
Authors: Lau David K. , Luk Ian Y. , Jenkins Laura J. , Martin Andrew , Williams David S. , Schoffer Kael L. , Chionh Fiona , Buchert Michael , Sjoquist Katrin , Boussioutas Alex , Hayes Sarah A. , Ernst Matthias , Weickhardt Andrew J. , Pavlakis Nick , Tebbutt Niall C. , Mariadason John M.
Published: April 2023

Supplementary Table 2
Figure S7 from Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK
Authors: Lau David K. , Luk Ian Y. , Jenkins Laura J. , Martin Andrew , Williams David S. , Schoffer Kael L. , Chionh Fiona , Buchert Michael , Sjoquist Katrin , Boussioutas Alex , Hayes Sarah A. , Ernst Matthias , Weickhardt Andrew J. , Pavlakis Nick , Tebbutt Niall C. , Mariadason John M.
Published: April 2023

Supplementary Figure 7
Supplementary Figure S1 from Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent
Authors: Yang Eddy S. , Nassar Amin H. , Adib Elio , Jegede Opeyemi A. , Alaiwi Sarah Abou , Manna Deborah L. Della , Braun David A. , Zarei Mahsa , Du Heng , Pal Sumanta K. , Naik Gurudatta , Sonpavde Guru P.
Published: April 2023

CONSORT diagram for the phase I/II trial of everolimus with and without BNC105P
Figure S5 from Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK
Authors: Lau David K. , Luk Ian Y. , Jenkins Laura J. , Martin Andrew , Williams David S. , Schoffer Kael L. , Chionh Fiona , Buchert Michael , Sjoquist Katrin , Boussioutas Alex , Hayes Sarah A. , Ernst Matthias , Weickhardt Andrew J. , Pavlakis Nick , Tebbutt Niall C. , Mariadason John M.
Published: April 2023

Supplementary Figure 5
Figure S3 from Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK
Authors: Lau David K. , Luk Ian Y. , Jenkins Laura J. , Martin Andrew , Williams David S. , Schoffer Kael L. , Chionh Fiona , Buchert Michael , Sjoquist Katrin , Boussioutas Alex , Hayes Sarah A. , Ernst Matthias , Weickhardt Andrew J. , Pavlakis Nick , Tebbutt Niall C. , Mariadason John M.
Published: April 2023

Supplementary Figure 3
Supplementary Tables from Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma
Authors: Tang Tracy T. , Konradi Andrei W. , Feng Ying , Peng Xiao , Ma Mingyue , Li Jian , Yu Fa-Xing , Guan Kun-Liang , Post Leonard
Published: April 2023

Supplementary Tables
Supplementary Figure from Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors
Authors: Tomar Sakshi , Zhang Jingli , Khanal Manakamana , Hong Jessica , Venugopalan Abhilash , Jiang Qun , Sengupta Manjistha , Miettinen Markku , Li Nan , Pastan Ira , Ho Mitchell , Hassan Raffit
Published: April 2023

Supplementary Figure from Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors
Supplementary Figure S4 from NAP1051, a Lipoxin A4 Biomimetic Analogue, Demonstrates Antitumor Activity Against the Tumor Microenvironment
Authors: Dong Tiange , Dave Priyal , Yoo EunJeong , Ebright Brandon , Ahluwalia Kabir , Zhou Eugene , Asante Isaac , Salimova Malika , Pei Hua , Lin Tracey , Mead Andrew , Li Zeyang , Humayun Mark , Petasis Nicos A. , Epstein Alan L. , Louie Stan G.
Published: April 2023

Figure S4 shows the gating strategy for analysis of myeloid cell subpopulations in the spleen or tumor.
Supplementary Data from Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors
Authors: Tomar Sakshi , Zhang Jingli , Khanal Manakamana , Hong Jessica , Venugopalan Abhilash , Jiang Qun , Sengupta Manjistha , Miettinen Markku , Li Nan , Pastan Ira , Ho Mitchell , Hassan Raffit
Published: April 2023

Supplementary Data from Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors
Table S2 from Anti-Glypican-1 Antibody–drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1–Positive Cholangiocarcinoma
Authors: Yokota Keiichiro , Serada Satoshi , Tsujii Shigehiro , Toya Keisuke , Takahashi Tsuyoshi , Matsunaga Takashi , Fujimoto Minoru , Uemura Sunao , Namikawa Tsutomu , Murakami Ichiro , Kobayashi Shogo , Eguchi Hidetoshi , Doki Yuichiro , Hanazaki Kazuhiro , Naka Tetsuji
Published: April 2023

Table S2
Table S1 from Anti-Glypican-1 Antibody–drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1–Positive Cholangiocarcinoma
Authors: Yokota Keiichiro , Serada Satoshi , Tsujii Shigehiro , Toya Keisuke , Takahashi Tsuyoshi , Matsunaga Takashi , Fujimoto Minoru , Uemura Sunao , Namikawa Tsutomu , Murakami Ichiro , Kobayashi Shogo , Eguchi Hidetoshi , Doki Yuichiro , Hanazaki Kazuhiro , Naka Tetsuji
Published: April 2023

Table S1
Figure S1 from Anti-Glypican-1 Antibody–drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1–Positive Cholangiocarcinoma
Authors: Yokota Keiichiro , Serada Satoshi , Tsujii Shigehiro , Toya Keisuke , Takahashi Tsuyoshi , Matsunaga Takashi , Fujimoto Minoru , Uemura Sunao , Namikawa Tsutomu , Murakami Ichiro , Kobayashi Shogo , Eguchi Hidetoshi , Doki Yuichiro , Hanazaki Kazuhiro , Naka Tetsuji
Published: April 2023

Figure S1
Supplementary Table from Porcupine Inhibition Disrupts Mitochondrial Function and Homeostasis in WNT Ligand–Addicted Pancreatic Cancer
Authors: Aguilera Kristina Y. , Le Thuc , Riahi Rana , Lay Anna R. , Hinz Stefan , Saadat Edris A. , Vashisht Ajay A. , Wohlschlegel James , Donahue Timothy R. , Radu Caius G. , Dawson David W.
Published: April 2023

Supplementary Table from Porcupine Inhibition Disrupts Mitochondrial Function and Homeostasis in WNT Ligand–Addicted Pancreatic Cancer
Supplementary Data from Cellular-Resolution Imaging of Bystander Payload Tissue Penetration from Antibody-Drug Conjugates
Authors: Khera Eshita , Dong Shujun , Huang Haolong , de Bever Laureen , van Delft Floris L. , Thurber Greg M.
Published: April 2023

Supplementary Data
Supplementary Fig. S1-S21, Table S1-S5
Supplementary Table 2 from ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer
Authors: Ferrarini Isacco , Louie Anna , Zhou Lanlan , El-Deiry Wafik S.
Published: April 2023

Supplementary Table S2: differential blood cell count of mice treated with ONC212, 2-DG, or the combination of both agents.
Supplementary Data from CX-5461 Sensitizes DNA Damage Repair–proficient Castrate-resistant Prostate Cancer to PARP Inhibition
Authors: Lawrence Mitchell G. , Porter Laura H. , Choo Nicholas , Pook David , Grummet Jeremy P. , Pezaro Carmel J. , Sandhu Shahneen , Ramm Susanne , Luu Jennii , Bakshi Andrew , Goode David L. , Sanij Elaine , Pearson Richard B. , Hannan Ross D. , Simpson Kaylene J. , Taylor Renea A. , Risbridger Gail P. , Furic Luc
Published: April 2023

Supplementary Methods, Figures, and Tables
Supplementary Methods from ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer
Authors: Ferrarini Isacco , Louie Anna , Zhou Lanlan , El-Deiry Wafik S.
Published: April 2023

Supplementary Methods
Supplementary Movie 8 from Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors
Authors: Keddy Clare , Shinde Pushkar , Jones Kristen , Kaech Stefanie , Somwar Romel , Shinde Ujwal , Davare Monika A.
Published: April 2023

Supplementary Movie 8
Time-lapse movie of live confocal imaging.
Supplementary Movie 6 from Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors
Authors: Keddy Clare , Shinde Pushkar , Jones Kristen , Kaech Stefanie , Somwar Romel , Shinde Ujwal , Davare Monika A.
Published: April 2023

Supplementary Movie 6
Time-lapse movie of live confocal imaging.
Supplementary Movie 2 from Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors
Authors: Keddy Clare , Shinde Pushkar , Jones Kristen , Kaech Stefanie , Somwar Romel , Shinde Ujwal , Davare Monika A.
Published: April 2023

Supplementary Movie 2
Time-lapse movie of live confocal imaging.
Supplementary Methods and Figures S1 to S7 from CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment
Authors: Fujiwara Tomohiro , Yakoub Mohamed A. , Chandler Andrew , Christ Alexander B. , Yang Guangli , Ouerfelli Ouathek , Rajasekhar Vinagolu K. , Yoshida Aki , Kondo Hiroya , Hata Toshiaki , Tazawa Hiroshi , Dogan Yildirim , Moore Malcolm A.S. , Fujiwara Toshiyoshi , Ozaki Toshifumi , Purdue Ed , Healey John H.
Published: April 2023

Supplementary data file shows supplementary methods and figures S1 to S7. Supplementary Figure S1 shows the establishment of the in vitro sarcoma TAM model. Supplementary Figure S2 shows the effect of anti-CSF-1 and anti-CSF-1R mAb and pazopanib on in vitro sarcoma TAMs. Supplementary Figure S3 show spontaneous lung metastasis in LM8 orthotopic osteosarcoma mouse model. Supplementary Figure S4 shows CSF-1R inhibition by PLX3397 blocks LM8-luc tumor growth and lung metastasis in orthotopic osteosarcoma mouse model. Supplementary Figure S5 shows toxicity assessment by body weight and blood chemistry per treatment group at the end of therapeutic experiments (day 22). Supplementary Figure S6 show histopathological examination of orthotopic osteosarcoma mouse models. Supplementary Figure S7 shows alteration of the TME composition in PLX3397-treated mice after CSF-1R inhibition
Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis
Authors: Bruce Shaina F. , Cho Kevin , Noia Hollie , Lomonosova Elena , Stock Elizabeth C. , Oplt Alyssa , Blachut Barbara , Mullen Mary M. , Kuroki Lindsay M. , Hagemann Andrea R. , McCourt Carolyn K. , Thaker Premal H. , Khabele Dineo , Powell Matthew A. , Mutch David G. , Shriver Leah P. , Patti Gary J. , Fuh Katherine C.
Published: April 2023

Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis
Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis
Authors: Bruce Shaina F. , Cho Kevin , Noia Hollie , Lomonosova Elena , Stock Elizabeth C. , Oplt Alyssa , Blachut Barbara , Mullen Mary M. , Kuroki Lindsay M. , Hagemann Andrea R. , McCourt Carolyn K. , Thaker Premal H. , Khabele Dineo , Powell Matthew A. , Mutch David G. , Shriver Leah P. , Patti Gary J. , Fuh Katherine C.
Published: April 2023

Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis
Supplementary table TS1 from Neoadjuvant Radiation Therapy and Surgery Improves Metastasis-Free Survival over Surgery Alone in a Primary Mouse Model of Soft Tissue Sarcoma
Authors: Patel Rutulkumar , Mowery Yvonne M. , Qi Yi , Bassil Alex M. , Holbrook Matt , Xu Eric S. , Hong Cierra S. , Himes Jonathon E. , Williams Nerissa T. , Everitt Jeffrey , Ma Yan , Luo Lixia , Selitsky Sara R. , Modliszewski Jennifer L. , Gao Junheng , Jung Sin-Ho , Kirsch David G. , Badea Cristian T.
Published: April 2023

Supplementary table 1
Supplementary figure FS2 from Neoadjuvant Radiation Therapy and Surgery Improves Metastasis-Free Survival over Surgery Alone in a Primary Mouse Model of Soft Tissue Sarcoma
Authors: Patel Rutulkumar , Mowery Yvonne M. , Qi Yi , Bassil Alex M. , Holbrook Matt , Xu Eric S. , Hong Cierra S. , Himes Jonathon E. , Williams Nerissa T. , Everitt Jeffrey , Ma Yan , Luo Lixia , Selitsky Sara R. , Modliszewski Jennifer L. , Gao Junheng , Jung Sin-Ho , Kirsch David G. , Badea Cristian T.
Published: April 2023

Additional lung abnormalities noted on CT and histology
Supplementary figure FS1 from Neoadjuvant Radiation Therapy and Surgery Improves Metastasis-Free Survival over Surgery Alone in a Primary Mouse Model of Soft Tissue Sarcoma
Authors: Patel Rutulkumar , Mowery Yvonne M. , Qi Yi , Bassil Alex M. , Holbrook Matt , Xu Eric S. , Hong Cierra S. , Himes Jonathon E. , Williams Nerissa T. , Everitt Jeffrey , Ma Yan , Luo Lixia , Selitsky Sara R. , Modliszewski Jennifer L. , Gao Junheng , Jung Sin-Ho , Kirsch David G. , Badea Cristian T.
Published: April 2023

SU2C-SARC032 clinical trial study design
Supplementary Figure from Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma
Authors: Cayrol Florencia , Revuelta Maria V. , Debernardi Mercedes , Paulazo Alejandra , Phillip Jude M. , Zamponi Nahuel , Sterle Helena , Díaz Flaqué María C. , Magro Cynthia , Marullo Rossella , Mulvey Erin , Ruan Jia , Cremaschi Graciela A. , Cerchietti Leandro
Published: April 2023

Supplementary Figure from Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma
Supplementary Tables S1-7 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
Authors: Peng Peng , Qiang Xiaoyan , Li Guoyu , Li Lin , Ni Shumao , Yu Qi , Sourd Laura , Marangoni Elisabetta , Hu Chao , Wang Dong , Wu Di , Wu Frank
Published: April 2023

Supplementary Tables
Figure FS9 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
Authors: Peng Peng , Qiang Xiaoyan , Li Guoyu , Li Lin , Ni Shumao , Yu Qi , Sourd Laura , Marangoni Elisabetta , Hu Chao , Wang Dong , Wu Di , Wu Frank
Published: April 2023

Tinengotinib possesses robust immunomodulatory activity.
Figure FS4 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
Authors: Peng Peng , Qiang Xiaoyan , Li Guoyu , Li Lin , Ni Shumao , Yu Qi , Sourd Laura , Marangoni Elisabetta , Hu Chao , Wang Dong , Wu Di , Wu Frank
Published: April 2023

Tinengotinib indirectly blocks EGFR signaling pathway without affecting PTPN12.
Figure FS3 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
Authors: Peng Peng , Qiang Xiaoyan , Li Guoyu , Li Lin , Ni Shumao , Yu Qi , Sourd Laura , Marangoni Elisabetta , Hu Chao , Wang Dong , Wu Di , Wu Frank
Published: April 2023

Tinengotinib effectively blocks Aurora kinase signaling pathway.
Supplementary Figures S1-S4 and Supplementary Tables from Sensitization to Ionizing Radiation by MEK Inhibition Is Dependent on SNAI2 in Fusion-Negative Rhabdomyosarcoma
Authors: Hensch Nicole R. , Bondra Kathryn , Wang Long , Sreenivas Prethish , Zhao Xiang R. , Modi Paulomi , Vaseva Angelina V. , Houghton Peter J. , Ignatius Myron S.
Published: April 2023

Supplementary Figures and Tables
Supplementary Data from Modular Smart Molecules for PSMA-Targeted Chemotherapy
Authors: Olatunji Feyisola P. , Pun Michael , Herman Jacob W. , Romero Oscar , Maniatopoulos Mitchell , Latoche Joseph D. , Parise Robert A. , Guo Jianxia , Beumer Jan H. , Anderson Carolyn J. , Berkman Clifford E.
Published: April 2023

Supplementary Data from Modular Smart Molecules for PSMA-Targeted Chemotherapy
Supplementary Table S1 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
Authors: Evans Rachel J. , Perkins Douglas W. , Selfe Joanna , Kelsey Anna , Birch Gavin P. , Shipley Janet M. , Schipper Koen , Isacke Clare M.
Published: April 2023

Antibodies and their dilutions
Supplementary Figure S4 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
Authors: Evans Rachel J. , Perkins Douglas W. , Selfe Joanna , Kelsey Anna , Birch Gavin P. , Shipley Janet M. , Schipper Koen , Isacke Clare M.
Published: April 2023

Composition and drug to antibody ratio of A5/158 and the isotype control antibody conjugated to vc-MMAE. This figure additionally shows that that conjugation of A5/158 and the isotype control antibody to vc-MMAE does not induce antibody aggregation or disrupt Endo180 protein recognition.
Supplementary Figure S2 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
Authors: Evans Rachel J. , Perkins Douglas W. , Selfe Joanna , Kelsey Anna , Birch Gavin P. , Shipley Janet M. , Schipper Koen , Isacke Clare M.
Published: April 2023

Endo180 protein and gene expression in healthy human tissue compared to sarcoma subtypes.
Supplementary Figure from TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor
Authors: Jo Ukhyun , Murai Yasuhisa , Agama Keli K. , Sun Yilun , Saha Liton Kumar , Yang Xi , Arakawa Yasuhiro , Gayle Sophia , Jones Kelli , Paralkar Vishwas , Sundaram Ranjini K. , Van Doorn Jinny , Vasquez Juan C. , Bindra Ranjit S. , Choi Woo Suk , Pommier Yves
Published: April 2023

Supplementary Figure from TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor
Suppl Figure 5 from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER
Authors: Hsu Jeff , Chong Colin , Serrill Jeffrey , Goon Levina , Balayan Joan , Johnson Eric N. , Lorenzana Grachelle , Wu Sharon , Leong Kevin G. , Yun Theodore J. , Wang Yong , Jiang Faming , Bannen Lynne , Lamb Peter , Xu Wei , Yu Peiwen
Published: April 2023

Suppl Figure 5
Suppl Figure 2 from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER
Authors: Hsu Jeff , Chong Colin , Serrill Jeffrey , Goon Levina , Balayan Joan , Johnson Eric N. , Lorenzana Grachelle , Wu Sharon , Leong Kevin G. , Yun Theodore J. , Wang Yong , Jiang Faming , Bannen Lynne , Lamb Peter , Xu Wei , Yu Peiwen
Published: April 2023

Suppl Figure 2
Supplementary Figure from HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations
Authors: Du Yong , Chen Yongfeng , Wang Yuxia , Chen Jinju , Lu Xiaorong , Zhang Li , Li Yan , Wang Zhaofu , Ye Guozhong , Zhang George
Published: April 2023

Supplementary Figure from HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations
Supplementary Table S2 from Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo
Authors: Jonchere Barbara , Williams Justin , Zindy Frederique , Liu Jingjing , Robinson Sarah , Farmer Dana M. , Min Jaeki , Yang Lei , Stripay Jennifer L. , Wang Yingzhe , Freeman Burgess B. , Yu Jiyang , Shelat Anang A. , Rankovic Zoran , Roussel Martine F.
Published: April 2023

Supplementary Table S2
Supplementary Methods, Figures and Tables from Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo
Authors: Jonchere Barbara , Williams Justin , Zindy Frederique , Liu Jingjing , Robinson Sarah , Farmer Dana M. , Min Jaeki , Yang Lei , Stripay Jennifer L. , Wang Yingzhe , Freeman Burgess B. , Yu Jiyang , Shelat Anang A. , Rankovic Zoran , Roussel Martine F.
Published: April 2023

Supplementary Methods, Figures S1-S9 and Tables S3, S5-S7
Data from Griseofulvin Radiosensitizes Non–Small Cell Lung Cancer Cells and Activates cGAS
Authors: Wang Xing , Raman Natasha , Lemtiri-Chlieh Ghali , Chang Jinhee , Jagtap Shreya , Chowdhury Dipanwita Dutta , Ballew Matthew , Carrieri Francesca Anna , Nguyen Triet , Nugent Katriana , Peck Travis , Levine Michelle S. , Chan Aaron , Lam Christine , Malek Reem , Hoang Tung , Phillips Ryan , Cheng ZhuoAn , Taparra Kekoa , Connis Nick , Hann Christine L. , Holland Andrew , Tran Phuoc T. , Lafargue Audrey , Wang Hailun
Published: April 2023

Abstract
Extra copies of centrosomes are frequently observed in cancer cells. To survive and proliferate, cancer cells have developed strategies to cluster extra-centrosomes to form bipolar mitotic spindles. The aim of this study was to investigate whether centrosome clustering (CC) inhibition (CCi) would preferentially radiosensitize non–small cell lung cancer (NSCLC). Griseofulvin (GF; FDA-approved treatment) inhibits CC, and combined with radiation treatment (RT), resulted in a significant increase in the number of NSCLC cells with multipolar spindles, and decreased cell viability and colony formation ability in vitro. In vivo, GF treatment was well tolerated by mice, and the combined therapy of GF and radiation treatment resulted in a significant tumor growth delay. Both GF and radiation treatment also induced the generation of micronuclei (MN) in vitro and in vivo and activated cyclic GMP-AMP synthase (cGAS) in NSCLC cells. A significant increase in downstream cGAS-STING pathway activation was seen after combination treatment in A549 radioresistant cells that was dependent on cGAS. In conclusion, GF increased radiation treatment efficacy in lung cancer preclinical models in vitro and in vivo. This effect may be associated with the generation of MN and the activation of cGAS. These data suggest that the combination therapy of CCi, radiation treatment, and immunotherapy could be a promising strategy to treat NSCLC.